Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P030011/S097

SynCardia Total Artificial Heart (STAH) System

Syncardia Systems, LLC · Decision date Feb 20, 2026

FDA DECISIONP030011/S097

What did the FDA approve?

FDA records P030011/S097 as a supplement to PMA P030011, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Feb 20, 2026.

FDA approval order statement

Approval for changes in the sterilization, heat shrink and packaging of the Companion 2 Driver Drivelines.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Feb 20, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P030011/S097
Regulatory pathway
PMA supplement
Product code
LOZ
Decision code
APPR
Decision date
Feb 20, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Artificial heart.

Product code
LOZ
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P030011/S097 received

    Application receipt date recorded by FDA.

  2. P030011/S096 · Related supplement

    SynCardia Total Artificial Heart (STAH) system

  3. P030011/S097 · FDA decision

    Real-Time Process

  4. P030011/S099 · Related supplement

    SynCardia Temporary Total Artificial Heart (TAH-t) System Freedom Driver System

Timeline entries are records held by MedtechLedger for P030011. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P030011

Product / regulatory recordCompanyPathwayDecision dateSource
Syncardia Systems, LLCPMA supplementNov 19, 2025FDA
Syncardia Systems, LLCPMA supplementDec 17, 2025FDA
Syncardia Systems, LLCPMA supplementJul 9, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Syncardia Systems, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1992 E. Silverlake Rd., Tucson, AZ, 85713

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records